Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Dec;99(8):861-870.
doi: 10.1111/aos.14786. Epub 2021 Mar 15.

Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study

Manuel Saenz-de-Viteri  1   2   3 , Sergio Recalde  2   3   4 , Patricia Fernandez-Robredo  2   3   4 , María Isabel López Gálvez  5 , Lluís Arias Barquet  3   6 , Marta S Figueroa  7 , José García-Arumí  8 , Alfredo García-Layana  1   2   3   4 ; In-Eye Study Group
Collaborators, Affiliations
Free article
Clinical Trial

Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study

Manuel Saenz-de-Viteri et al. Acta Ophthalmol. 2021 Dec.
Free article

Abstract

Purpose: To assess the effect of fluid status at baseline (BL) and at the end of the loading phase (LP) of three different ranibizumab regimens: treat-and-extend (T&E), fixed bimonthly (FBM) injections and pro re nata (PRN), in patients with neovascular age-related macular degeneration (nAMD).

Design: Post hoc analysis of the In-Eye study (phase IV clinical trial).

Methods: Patients were randomized 1:1:1 to the three study arms and were treated accordingly. The presence and type of fluid, intraretinal fluid (IRF) or subretinal fluid (SRF) and the anatomical and visual outcomes were analysed.

Main outcome measures: Best-corrected visual acuity (BCVA), the mean change from baseline BCVA (BL BCVA), and the proportion of eyes gaining more than 15 letters or losing more than five letters were analysed. Morphological characteristics including the subtype of choroidal neovascular membrane and the development of atrophy and fibrosis were also evaluated.

Results: Patients with SRF at LP had better visual outcomes than patients with IRF. The persistence of SRF did not affect the mean change from BL BCVA among the three treatment regimens. However, in patients with IRF mean change from BL BCVA was significantly lower in the FBM group. The presence of IRF at BL and at the end of the loading phase was associated with the development of fibrosis at the end of the study; this result was contrary to that observed for patients with SRF.

Conclusions: While SRF is compatible with good visual and anatomical outcomes, IRF leads to worse results in patients with nAMD; our results suggest that patients with IRF have better outcomes when individualized treatment regimens are used (PRN or T&E) in contrast with a FBM regimen.

Keywords: age-related macular degeneration; fixed bimonthly; intraretinal fluid; intravitreal anti-VEGF; neovascular age-related macular degeneration; pro re nata; ranibizumab; subretinal fluid; treat-and-extend.

PubMed Disclaimer

References

    1. Amoaku WM, Chakravarthy U, Gale R et al. (2015): Defining response to anti-VEGF therapies in neovascular AMD. Eye 29: 721-731.
    1. Arnold JJ, Markey CM, Kurstjens NP & Guymer RH (2016): The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - A phase IV randomised clinical trial with ranibizumab: The FLUID study. BMC Ophthalmol 16: 1-9.
    1. Ashraf M, Souka A & Adelman RA (2018): Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol 96: 120-133.
    1. Bailey C, Scott LJ, Rogers CA, Reeves BC, Hamill B, Peto T, Chakravarthy U & Harding SP (2019): Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial. Ophthalmology 26: 75-86.
    1. Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR & Zhang K (2015): Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 159: 915-924.e2.

Publication types

MeSH terms

Substances

LinkOut - more resources